REMARKS

Applicant became aware of a computer software-generated error message, which appeared in the specification as originally filed and was previously undetected. Support for the corrections to the specification can be found in PCT/DK03/00449, published as WO 2004/002481. The present application is a continuation of the above-identified International Application, the contents of which were also incorporated by reference.

Applicant has also corrected minor, apparent typographical errors in the specification. No new matter will be introduced as a result of the entry of this amendment

The examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: April 14, 2006

Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5969

Use the following customer number for all correspondence regarding this application.

23650